These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 9204233)

  • 41. Women as moral pioneers? Experiences of first trimester antenatal screening.
    Williams C; Sandall J; Lewando-Hundt G; Heyman B; Spencer K; Grellier R
    Soc Sci Med; 2005 Nov; 61(9):1983-92. PubMed ID: 15899542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maternal serum screening for fetal genetic disorders.
    Ross HL; Elias S
    Obstet Gynecol Clin North Am; 1997 Mar; 24(1):33-47. PubMed ID: 9086517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Refinements in managing maternal weight adjustment for interpreting prenatal screening results.
    Neveux LM; Palomaki GE; Larrivee DA; Knight GJ; Haddow JE
    Prenat Diagn; 1996 Dec; 16(12):1115-9. PubMed ID: 8994247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Serum analysis in pregnant women. Mass screening is an effective way to discover chromosome aberrations--arguments for and against].
    Kristoffersson U; Nørgaard-Pedersen B
    Lakartidningen; 1995 Mar; 92(12):1205-6, 1211-2. PubMed ID: 7535873
    [No Abstract]   [Full Text] [Related]  

  • 45. Major fetal abnormalities associated with positive screening tests for Smith-Lemli-Opitz syndrome (SLOS).
    Craig WY; Haddow JE; Palomaki GE; Roberson M
    Prenat Diagn; 2007 May; 27(5):409-14. PubMed ID: 17286308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Serum screening in pregnant women for Down syndrome and open neural-tube defects; testing against the Health Council criteria for genetic screening].
    Wildhagen MF; Christiaens GC; Habbema JD
    Ned Tijdschr Geneeskd; 1996 Jan; 140(2):85-9. PubMed ID: 8569927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prenatal genetic screening: biochemical markers of the first and second quarter].
    Grether González P; Aguinaga Ríos M;
    Ginecol Obstet Mex; 2009 Feb; 77(2):S27-46. PubMed ID: 19365955
    [No Abstract]   [Full Text] [Related]  

  • 49. [Screening for Down syndrome using first-trimester combined screening followed by second trimester ultrasound examination in an unselected population].
    Rozenberg P; Bussières L; Chevret S; Bernard JP; Malagrida L; Cuckle H; Chabry C; Durand-Zaleski I; Bidat L; Lacroix I; Moulis M; Roger M; Jacquemot MC; Bault JP; Boukobza P; Boccara P; Vialat F; Giudicelli Y; Ville Y
    Gynecol Obstet Fertil; 2007 Apr; 35(4):303-11. PubMed ID: 17350315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An update on antenatal screening for Down's syndrome and specific implications for assisted reproduction pregnancies.
    Weisz B; Rodeck CH
    Hum Reprod Update; 2006; 12(5):513-8. PubMed ID: 16672245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maternal smoking during pregnancy and false positive maternal serum alpha-fetoprotein (MSAFP) screening for open neural tube defects.
    Urato AC; Quinn R; Pulkkinen A; Craigo SD; Allan W
    Prenat Diagn; 2008 Aug; 28(8):778-80. PubMed ID: 18551721
    [No Abstract]   [Full Text] [Related]  

  • 52. Alpha-fetoprotein.
    Drugan A; Dvorin E; Obrien JE; Johnson MP; Evans MI
    Curr Opin Obstet Gynecol; 1991 Apr; 3(2):230-4. PubMed ID: 1717020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First and second-trimester biochemical markers of chromosomal anomalies and their relationship to maternal haemoglobin levels.
    Cowans NJ; Spencer K
    Prenat Diagn; 2005 Aug; 25(8):693-9. PubMed ID: 16050001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prenatal screening for major fetal defects by using of maternal serum markers].
    Bao P; Wu Y; Gu Q
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):649-51. PubMed ID: 9639762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prenatal screening for open neural tube defects and Down syndrome: three decades of progress.
    Wald NJ
    Prenat Diagn; 2010 Jul; 30(7):619-21. PubMed ID: 20572104
    [No Abstract]   [Full Text] [Related]  

  • 56. Insulin-dependent diabetes mellitus and prenatal screening results: current experience from a regional screening programme.
    Crossley JA; Berry E; Aitken DA; Connor JM
    Prenat Diagn; 1996 Nov; 16(11):1039-42. PubMed ID: 8953638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [First trimester ultrasound screening for nuchal translucency as marker of Down's syndrome].
    Herman A; Maymon R; Dreazen E; Bukovsky I; Weinraub Z
    Harefuah; 1997 Jan; 132(2):94-100. PubMed ID: 9119309
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical evaluation of a single antibody RIA assay for alpha-fetoprotein.
    Needleman SB; Goldstein AI; Johnson AM; Golubjatnikov R; Ward AM; Fifield R
    J Reprod Med; 1980 Sep; 25(3):101-7. PubMed ID: 6159471
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical screening.
    Evans MI; O'Brien JE; Dvorin E; Johnson MP
    Curr Opin Obstet Gynecol; 1994 Oct; 6(5):453-8. PubMed ID: 7827277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Determination of maternal serum alpha fetoprotein with a Polish AFP radioimmunoassay--a suitable screening method for neural tube defects?].
    Schlosser H; Greiff R
    Zentralbl Gynakol; 1986; 108(15):914-8. PubMed ID: 2429479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.